Cost-effectiveness of smoking cessation and the implications for COPD

Figures & data

Table 1 Summary of studies reporting cost of quality adjusted life years/life years saved through various smoking cessation programs

Study	Cost perspective	Cost measurement	Study design	Criteria for successful quit	Discount rate	Background quit/relapse rate	Cost
Javitz et al (2004a)	Program	QALY/LYS	4 groups (2 doses bupropion, 2 behavioral interventions)	7 day abstinence at 12 months	3%	1.5%/37%	a$512–$2047/QALY $116–$3590 (post SA)/ QALY $528–$2194/LYS $106–$4295 (post SA) / LYS
Feenstra et al (2005)	Program	QALY/LYS	Dynamic computer simulation over 75-year time horizon	Permanent quit	4%	NA/NA	€1100–€4900/QALY €1400–€6200/LYS
Tran et al (2002)	Payer	QALY	Pharmacist vs patient-directed	12 months of continued abstinence	3%	3%/75%	$450–$578 $141–$2258 (post SA)
Warner et al (1996)	Employer	LYS	Computer simulation cumulative over lifetime	Permanent quit	3.5%	2.5%/85%	$894 (at age 85 years)
Wasley et al (1997)	Program	LYS	Counseling with and without nicotine replacement	12 month abstinence	5%	1%/35%	$362–$4391 $379–$6364 (post SA)
Curry et al (1998)	Payer	LYS	4 plans with different financial investment by smokers	7 day abstinence at 6 months	3%	NA/NA	$928–$1192
Lennox et al (2001)	Program	LYS	Individualized vs standardized letters sent to participants	6-month quit rate	5%	NA/NA	£50–£122
Gilbert et al (2004)	Payer	LYS	Counseling alone vs any of 5 pharmacological interventions with follow-up counseling	Not specified	3%	2.5%/35%	$1311–$9777
Tomson et al (2004)	Program	LYS	Free quitline in Sweden over 2-year period	No use within previous 7 days	3–5%	NA/NA	$311–$401 $311–$1607 (post SA)
Godfrey et al (2005)	Program	LYS	Summary of cessation services in England (coordinator survey)	Abstinence at 4 weeks (Converted to 12 months)	3.5%	2%/65%	£557–£811 £438–£2293 (post SA)

a US$

Abbreviations: LYS, life-years saved; NA, not available; QALY, quality adjusted life year; SA, sensitiviy analysis.

JavitzHSSwanGEZbikowskiSM2004aCost-effectiveness of different combinations of bupropion SR dose and behavioral treatment for smoking cessation: a societal perspectiveAm J Manag Care102172615032259

 PubMed Web of Science ®Google Scholar

FeenstraTLHamberg-van ReenenHHHoogenveenRT2005Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling studyValue Health81789015877590

 PubMed Web of Science ®Google Scholar

TranMTHoldfordDAKennedyDT2002Modeling the cost-effectiveness of a smoking-cessation program in a community pharmacy practicePharamcotherapy22162331

 Web of Science ®Google Scholar

WarnerKESmithRJSmithDG1996Health and economic implications of a work-site smoking-cessation program: a simulation analysisJ Occup Environ Med38981928899574

 PubMed Web of Science ®Google Scholar

WasleyMAMcNagnySEPhillipsVL1997The cost-effectiveness of the nicotine transdermal patch for smoking cessationPrev Med26264709085397

 PubMed Web of Science ®Google Scholar

CurrySJGrothausLCMcAfeeT1998Use and cost effectiveness of smoking-cessation services under four insurance plans in a health maintenance organizationN Engl J Med339673799725926

 PubMed Web of Science ®Google Scholar

LennoxASOsmanLMReiterE2001Cost effectiveness of computer tailored and non-tailored smoking cessation letters in general practice: randomized controlled trialBMJ322139640111397745

 PubMed Web of Science ®Google Scholar

GilbertARPingetCBovetP2004The cost effectiveness of pharmacological smoking cessation therapies in developing countries: a case study in the SeychellesTobacco Control13190515175539

 PubMed Web of Science ®Google Scholar

TomsonTHelgasonARGilljamH2004Quitline in smoking cessation: a cost-effectiveness analysisInt J Technol Assess Health Care204697415609797

 PubMed Web of Science ®Google Scholar

GodfreyCParrottSColemanT2005The cost-effectiveness of the English smoking treatment services: evidence from practiceAddiction100Suppl 2708315844290

 PubMed Web of Science ®Google Scholar